Citations

Clear

3042 citation(s) found for "Kumar, S".

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Ip, James E. , Coutu, Benoit , Noseworthy, Peter A. , Parody, Maria Leonor, Rafii, Farhad, Stambler, Bruce S. , Tahirkheli, Naeem , Uribe, Juan Fernando Agudelo , Hu, Derek , Shardonofsky, Silvia, Sheikh, Mohamud, Holz, Anita, Bharucha, David B. , Camm, A. John, Noseworthy, Peter A , Sears, Samuel F , Stambler, Bruce S , Agudelo-Uribe, Juan , Ip, James E. , Sears, Samuel F. , Singh, Narendra Kumar , Sheikh, Muhammad B., Holz, Anita, Camm, Alan John

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 11, 2025 | Volume: 36 | Issue: 11 | Pages: 2990-3003

10.1111/jce.70086 | PMID 40931676 Get It

ABSTRACT Introduction Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an open‐label, single‐arm study that evaluated etripamil for multiple, at‐home PSVT episodes, without test dose before first use. Methods Patients applied an ECG monitor at symptom onset and self‐administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70‐mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment‐emergent adverse events (TEAEs) and ECG arrhythmia‐surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes. Results 1054 perceived PSVT episodes were etripamil‐treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2–25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes. Conclusions Etripamil nasal spray self‐administered in a real‐world setting was well tolerated, effective, and had a consistent safety profile as a single‐ or repeat‐dose regimen across multiple PSVT episodes. Trial Registration: ClinicalTrials.gov NCT04072835
Improvement in Insulin Sensitivity Prevents Decline in Glucose Uptake, Functional Connectivity, and Volume in the Insulin Resistant Human Brain.
Nair, K. Sreekumaran , Klaus, Katherine A. , Sevits, Kyle J., Leija, Robert G. , Kumar, Arathi Prabha, Sinhawansa, Sumaiya, Dreconga, Martina, Carter, Rickey E. , Lowe, Val J. , Pataky, Mark W , Ruegsegger, Gregory, Klaus, Katherine, Sevits, Kyle , Leija, Robert, Kumar, Arathi, Carter, Rickey, Stricker, Nikki, Port, John D , Nair, K Sreekumaran , Carter, Rickey E , Ruegsegger, Gregory N. , Jo, Hang Joon , Lim, Seokbeen , Cobelli, Claudio , Stricker, Nikki H. , Port, John D.

Mayo Clinic

No container title available | September 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7462946/v1 | PMID 40964018 Get It

Abstract Insulin resistance (IR) is a modifiable risk factor for dementia, yet its effects on brain metabolism and function remain unclear. In older adults, greater IR was associated with reduced cerebral glucose uptake (indicating impaired mitochondrial metabolism), atrophy, and weakened connectivity between brain regions critical for cognition. In neuron-specific insulin receptor knockout mice, brain IR produced deficits in hippocampal- and prefrontal-dependent tasks accompanied by reduced brain mitochondrial ATP and elevated reactive oxygen species. To evaluate reversibility of IR-induced brain deficits, forty older adults with IR were randomized to 40-weeks of metformin or placebo. Metformin improved insulin sensitivity, increased brain glucose uptake, strengthened cognitive network connectivity, and preserved whole-brain and regional volumes implicated in decision-making and learning. Metformin also improved processing speed and working memory. Collectively, these findings highlight IR as a driver of brain metabolism and support the concept that insulin sensitization can prevent neurobiological deficits in older people with IR.
Rising Obesity-Related Cardiovascular Mortality in the United States, 1999–2020: Accelerating Trends and Widening Disparities
Pavuluri, Sai Swetha, Kataveni, Suhas , Trivedi, Shashank , Pasupuleti, Suman, Sahai, Akshat, Haidar, Salar, Vashisht, Kumar, Adithya, Vikram, Lanka, Nidhi, Sharma, Gaurav , Pasupuleti, Suman, Sahai, Akshat, Haidar, Salar

Mayo Clinic

No container title available | September 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7530128/v1 Get It

Abstract Obesity is a major and growing driver of cardiovascular disease (CVD) in the United States, contributing to hypertension, diabetes, dyslipidemia, and structural cardiac changes that elevate the risk of ischemic heart disease, heart failure, and stroke. After decades of declining CVD mortality, recent national trends show a concerning reversal, coinciding with record-high obesity prevalence. We quantified national trends and disparities in obesity-related CVD mortality from 1999–2020 using de-identified death certificate data from the CDC WONDER database for U.S. residents aged 15–84 years, including deaths with circulatory disease (ICD-10 I00–I99) as the underlying cause and obesity (E66.0–E66.9) as a contributing cause. Age-adjusted mortality rates (AAMR) standardized to the 2000 U.S. population were analyzed using joinpoint regression to estimate annual percent change (APC) and detect inflection points. From 1999–2018, AAMR rose from 2.75 to 6.61 per 100,000 (APC 4.79%; 95% CI 4.60–4.98), followed by a significant post-2018 acceleration (APC 11.05%; 95% CI 6.76–15.51) to 8.36 in 2020. Mortality was highest among adults 65–74 years, males, Black Americans, and nonmetropolitan residents, with a 5.1-fold state variation. Young adults (15–24 years) had the largest relative increase (+210%). The 2020 surge was independent of COVID-19 mortality, indicating gaps in chronic disease management. These results highlight a growing obesity-related CVD mortality burden, with widening disparities by age, sex, race, and geography, emphasizing urgent, equity-focused prevention and targeted interventions.
Sudden Death in Children and Young Adults: Etiologies, Risk Stratification, and Prevention Strategies
Ahmad, Rimsha , Arslan, Fatima Safi , Niaz, Mahnoor, Hussain, Syed Sadam, Frishman, William H., Aronow, Wilbert S., Khan, Saifullah , Kumar, Mahesh , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | September 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001043 | PMID 40910770 Get It

Sudden death in children and young adults, while uncommon, carries profound clinical and societal implications. Cardiac causes, particularly inherited arrhythmias and cardiomyopathies, account for most cases, though neurologic, toxicologic, traumatic, and infectious etiologies also contribute significantly. This review explores the epidemiology, classification, and pathophysiologic mechanisms of sudden death in this population, emphasizing early clinical warning signs and identifiable risk factors. We also outline diagnostic and preventive strategies, including electrocardiography, genetic testing, and postmortem evaluation. Despite guidelines advocating preparticipation screening, real-world implementation remains inconsistent. Advances in genomics and artificial intelligence offer new opportunities for early risk detection. Finally, we discuss public health interventions such as defibrillator access, cardiopulmonary resuscitation education, and school-based protocols as essential components of a broader prevention strategy.
Global and regional mortality rate statistics of mpox (formerly monkeypox): a comprehensive systematic review and meta-analysis
Vasudevan, Srivatsa Surya , Kandrikar, Tiba Yamin , Cooner, Prachi , Jeswani, Bijay Mukesh , Batarseh, Suhel F. , Sayed, Abdalla , Yadav, Ashmita , Pitliya, Aakanksha , Panchal, Riddhi , Vasudevan, A, Tuna, Hansala Nursah Yilmaz, DAPKE, KARTIK, Gondaliya, Piyush , Panchal, Riddhi , Sayed, Abdalla , Yadav, Ashmita , Kumar, Vijay , Li, Chun

Mayo Clinic

Pathogens and Global Health | August 30, 2025 | Volume: 119 | Issue: 7 | Pages: 293-303

10.1080/20477724.2025.2551507 | PMID 40884410 Get It

Real‐World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population‐Based Retrospective Cohort Study
Abdallah, Nadine , Mian, Hira , Seow, Hsien , Pond, Gregory P., Gayowsky, Anastasia , Fonseca, Rafael, Cook, Gordon , Kumar, Shaji , Pond, Gregory R. , Kumar, Shaji K , Chakraborty, Rajshekhar , Pond, Gregory Russell , Mian, Hira , Cook, Gordon , Visram, Alissa , Costa, Luciano J. , Wildes, Tanya M. , Fonseca, Rafael, Pawlyn, Charlotte , Chakraborty, Rajshekhar

Mayo Clinic

American Journal of Hematology | August 29, 2025 | Volume: 100 | Issue: 11 | Pages: 2144-2149

10.1002/ajh.70042 | PMID 40879697 Get It

Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups
Yadav, Sumeet K. , Joshi, Utsav , Hussein, Guleid , Warsame, Mohamed , Liu, Bolun , Shrestha, Abhash , Krastev, Peter, Singh, Amrit , Korsapati, Hariprasad Reddy , Yadav, Sumeet Kumar , Liu, Bolun

Mayo Clinic

Cancers | August 29, 2025 | Volume: 17 | Issue: 17 | Pages: 2824

10.3390/cancers17172824 | PMID 40940920 Get It

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal proliferation of myeloid precursors and rapid progression. Historically consisting of intensive chemotherapy, AML management has evolved significantly due to advances in molecular diagnostics and risk stratification. This review discusses current therapeutic paradigms in AML, emphasizing the growing role of personalized medicine across age and risk groups. For younger, fit patients, intensive regimens such as the “7 + 3” protocol remain the standard, often enhanced by targeted agents like FMS-like tyrosine kinase 3 (FLT3) and IDH inhibitors. Older or unfit individuals benefit from low-intensity treatments such as hypomethylating agents combined with venetoclax, now considered a frontline standard of care. The use of liposomal chemotherapy (CPX-351), measurable residual disease (MRD) monitoring, and maintenance therapy further refine post-remission strategies. Emerging therapies, including menin inhibitors, antibody–drug conjugates, and immunotherapies like CAR-T cells and vaccines, offer additional options, especially in relapsed/refractory settings. This comprehensive review outlines the current landscape and future directions in AML therapy, emphasizing the transition toward individualized, mutation-driven treatment strategies.
Outcomes of Reinduction With Nadofaragene Firadenovec
Schmidt, Bogdana, Horns, Joshua J. , Tyson, Mark D. , Linehan, Jennifer , Dickstein, Rian J., Daneshmand, Siamak , Agarwal, Piyush Kumar , Narayan, Vikram M. , Luckenbaugh, Amy N. , Lotan, Yair

Mayo Clinic

Journal of Urology | August 25, 2025 | Volume: 214 | Issue: 5 | Pages: 472-473

10.1097/ju.0000000000004697 | PMID 40852908 Get It

Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
Jang, Albert , Tripathi, Nikita , Lanka, Sree M , Calaway, Adam , Shoag, Jonathan E. , Vince, Randy , Mendiratta, Prateek, Rao, Santosh, García, Jorge A. , Koshkin, Vadim S. , Barata, Pedro C. , Calaway, Adam , Vince, Randy , Brown, Jason R , Koshkin, Vadim S , Barata, Pedro , Jang, Albert , Kumar, Hamsa L.S. , Jain, Prateek, Brown, Jason R. , Campbell, Matthew T. , Singh, Parminder

Mayo Clinic

The Oncologist | August 16, 2025 | Volume: 30 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyaf259 | PMID 40828887 Get It

Abstract The combination of enfortumab vedotin and pembrolizumab (EVP) has recently revolutionized care for patients with previously untreated locally advanced and metastatic urothelial carcinoma. However, predictive biomarkers of response, the optimal duration of EVP for patients who respond well to therapy, and the role of circulating tumor DNA to monitor treatment response have not yet been fully elucidated. In this molecular tumor board, we summarize 6 patients from 4 different academic institutions with unresectable or oligometastatic urothelial carcinoma who achieved long-term remission on surveillance after a short duration of EVP treatment that resulted in complete response on follow-up imaging followed by consolidative radical cystectomy. We discuss potential predictive biomarkers for patients with exceptional response to EVP. These findings highlight the need to determine an optimal duration of EVP to maximize efficacy while minimizing adverse events. We aim to further define and explore the value of local therapy with consolidative cystectomy in the setting of unresectable, locally advanced, oligometastatic disease, or those with metastatic disease who achieve complete response of disease outside of the bladder. Identifying this subset of patients who may be candidates for this type of multidisciplinary management may result in durable treatment-free remission.